The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Pain medication and long QT syndrome

  • Klivinyi, Christoph (Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz) ;
  • Bornemann-Cimenti, Helmar (Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz)
  • Received : 2017.06.07
  • Accepted : 2017.11.06
  • Published : 2018.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Long QT syndrome is a cardiac repolarization disorder and is associated with an increased risk of torsades de pointes. The acquired form is most often attributable to administration of specific medications and/or electrolyte imbalance. This review provides insights into the risk for QT prolongation associated with drugs frequently used in the treatment of chronic pain. In the field of pain medicine all the major drug classes (i.e. NSAIDs, opioids, anticonvulsive and antidepressant drugs, cannabinoids, muscle relaxants) contain agents that increase the risk of QT prolongation. Other substances, not used in the treatment of pain, such as proton pump inhibitors, antiemetics, and diuretics are also associated with long QT syndrome. When the possible benefits of therapy outweigh the associated risks, slow dose titration and electrocardiography monitoring are recommended.

Keywords

References

  1. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal 2012; 2012: 212178.
  2. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433-45. https://doi.org/10.1001/archinte.163.20.2433
  3. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 2008; 65: 1029-38. https://doi.org/10.2146/ajhp070279
  4. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-60. https://doi.org/10.1161/CIRCULATIONAHA.109.192704
  5. Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 2013; 29: 1719-26. https://doi.org/10.1185/03007995.2013.840568
  6. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 2017; 39: 16-25. https://doi.org/10.1007/s11096-016-0414-2
  7. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 2012; 92: 1393-478. https://doi.org/10.1152/physrev.00036.2011
  8. Koffeman AR, Valkhoff VE, Celik S, W't Jong G, Sturkenboom MC, Bindels PJ, et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 2014; 64: e191-8. https://doi.org/10.3399/bjgp14X677815
  9. Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8: 173-82. https://doi.org/10.1177/2042098617690485
  10. Nagele P, Pal S, Brown F, Blood J, Miller JP, Johnston J. Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia. Anesthesiology 2012; 117: 321-8. https://doi.org/10.1097/ALN.0b013e31825e6eb3
  11. Pathak A, Boveda S, Defaye P, Mansourati J, Mallaret M, Thebault L, et al. Celecoxib-associated torsade de pointes. Ann Pharmacother 2002; 36: 1290-1. https://doi.org/10.1345/aph.1A429
  12. Frolov RV, Ignatova II, Singh S. Inhibition of HERG potassium channels by celecoxib and its mechanism. PLoS One 2011; 6: e26344. https://doi.org/10.1371/journal.pone.0026344
  13. Kristof A, Husti Z, Koncz I, Kohajda Z, Szel T, Juhasz V, et al. Diclofenac prolongs repolarization in ventricular muscle with impaired repolarization reserve. PLoS One 2012; 7: e53255. https://doi.org/10.1371/journal.pone.0053255
  14. Westermeyer J, Adabag S, Anand V, Thuras P, Yoon G, Batres-Y-Carr T. Methadone maintenance dose/weight ratio, long QTc, and EKG screening. Am J Addict 2016; 25: 499-507. https://doi.org/10.1111/ajad.12423
  15. Grodofsky S, Edson E, Huang S, Speck RM, Hatchimonji J, Lacy K, et al. The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. Pain Med 2015; 16: 1112-21. https://doi.org/10.1111/pme.12658
  16. van den Beuken-van Everdingen MH, Geurts JW, Patijn J. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain. J Opioid Manag 2013; 9: 263-7. https://doi.org/10.5055/jom.2013.0167
  17. Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014; 15: 321-37. https://doi.org/10.1016/j.jpain.2014.01.494
  18. Emamhadi M, Sanaei-Zadeh H, Nikniya M, Zamani N, Dart RC. Electrocardiographic manifestations of tramadol toxicity with special reference to their ability for prediction of seizures. Am J Emerg Med 2012; 30: 1481-5. https://doi.org/10.1016/j.ajem.2011.12.009
  19. Keller GA, Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Belloso WH, et al. Tramadol induced QTcinterval prolongation: prevalence, clinical factors and correlation to plasma concentrations. Curr Drug Saf 2016; 11: 206-14. https://doi.org/10.2174/1574886311666160225150405
  20. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104: 993-9. https://doi.org/10.1111/j.1360-0443.2009.02549.x
  21. Stallvik M, Nordstrand B, Kristensen O, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations. Drug Alcohol Depend 2013; 129: 88-93. https://doi.org/10.1016/j.drugalcdep.2012.09.016
  22. Kao DP, Haigney MC, Mehler PS, Krantz MJ. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction 2015; 110: 1468-75. https://doi.org/10.1111/add.13013
  23. Poole SA, Pecoraro A, Subramaniam G, Woody G, Vetter VL. Presence or absence of QTc prolongation in buprenorphinenaloxone among youth with opioid dependence. J Addict Med 2016; 10: 26-33. https://doi.org/10.1097/ADM.0000000000000176
  24. Fanoe S, Jensen GB, Sjogren P, Korsgaard MP, Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol 2009; 67: 172-9. https://doi.org/10.1111/j.1365-2125.2008.03327.x
  25. Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM 2013; 106: 35-41. https://doi.org/10.1093/qjmed/hcs176
  26. Keller GA, Villa Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Diez RA, et al. Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations. Int J Clin Pharmacol Ther 2017; 55: 275-85. https://doi.org/10.5414/CP202612
  27. Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res 2005; 63: 17-25. https://doi.org/10.1016/j.eplepsyres.2004.10.002
  28. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008; 66: 396-404. https://doi.org/10.1111/j.1365-2125.2008.03250.x
  29. Davy M, Upward J, Arumugham T, Twomey C, Chen C, Stier B. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. Clin Ther 2013; 35: 1964-74. https://doi.org/10.1016/j.clinthera.2013.10.011
  30. Chen D, Lal R, Zomorodi K, Atluri H, Ho J, Luo W, et al. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. Clin Ther 2012; 34: 351-62.e3. https://doi.org/10.1016/j.clinthera.2012.01.002
  31. Alp R, Citil M, Uzun M, Alp S, Topcu B, Uzlu E, et al. Effects of therapeutic doses of Pregabalin on QTc interval in conscious rabbits. Eur Rev Med Pharmacol Sci 2008; 12: 223-8.
  32. Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010; 5: 105-11. https://doi.org/10.2174/157488610789869256
  33. Feldman AE, Gidal BE. QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy. Epilepsy Behav 2013; 26: 421-6. https://doi.org/10.1016/j.yebeh.2012.09.021
  34. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75: e441-9. https://doi.org/10.4088/JCP.13r08672
  35. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics 2015; 56: 36-43. https://doi.org/10.1016/j.psym.2014.09.002
  36. FDA Drug Safety Communication. Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses [Internet]. Rockville, MD: Food and Drug Administration; 2012 [cited 2017 Oct 2]. Available at https://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
  37. Carceller-Sindreu M, de Diego-Adelino J, Portella MJ, Garcia-Moll X, Figueras M, Fernandez-Vidal A, et al. Lack of relationship between plasma levels of escitalopram and QTc-interval length. Eur Arch Psychiatry Clin Neurosci 2017; 267: 815-22. https://doi.org/10.1007/s00406-016-0758-6
  38. Unterecker S, Pfuhlmann B, Kopf J, Kittel-Schneider S, Reif A, Deckert J. Increase of heart rate and QTc by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol 2015; 35: 460-3.
  39. Jasiak NM, Bostwick JR. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother 2014; 48: 1620-8. https://doi.org/10.1177/1060028014550645
  40. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006; 109: 116-7. https://doi.org/10.1016/j.ijcard.2005.03.065
  41. Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol 2005; 510: 75-85. https://doi.org/10.1016/j.ejphar.2005.01.009
  42. Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol 1982; 23: 417-21. https://doi.org/10.1007/BF00605991
  43. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456-73. https://doi.org/10.1001/jama.2015.6358
  44. Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, et al. A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD spray. Clin Pharmacol Drug Dev 2013; 2: 285-94. https://doi.org/10.1002/cpdd.36
  45. Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, et al. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res 2016; 5: 1663-71. https://doi.org/10.1039/C6TX00259E
  46. Kaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther 2012; 17: 102-9. https://doi.org/10.1177/1074248410395020
  47. Yamagiwa T, Morita S, Amino M, Miura N, Saito T, Inokuchi S. Serum concentration of eperisone hydrochloride correlates with QT interval. Am J Emerg Med 2014; 32: 75-7. https://doi.org/10.1016/j.ajem.2013.09.006
  48. Kovac AL. Comparative pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting. Drugs 2016; 76: 1719-35. https://doi.org/10.1007/s40265-016-0663-3
  49. Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf 2011; 3: 53-8.
  50. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med 2014; 64: 19-25. https://doi.org/10.1016/j.annemergmed.2013.10.026
  51. FDA Drug Safety Communication. Abnormal heart rhythms ass ociated with use of Anzemet (dolasetron mesylate) [Internet]. Rockville, MD: U.S Food and Drug Administration; 2010 [cited 2017 Oct 2]. Available at https://www.fda. gov/Drugs/DrugSa fety/ucm237081.htm#safety_announcement.
  52. Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005; 28: 201-4. https://doi.org/10.1097/01.coc.0000144849.41300.0a
  53. Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 2012; 18: 2913-21. https://doi.org/10.1158/1078-0432.CCR-11-2785
  54. Carmichael J, Harris AL. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003; 14: 739-44.
  55. Judkins KC, Harmer M. Haloperidol as an adjunct analgesic in the management of postoperative pain. Anaesthesia 1982; 37: 1118-20. https://doi.org/10.1111/j.1365-2044.1982.tb01759.x
  56. Maltbie AA, Cavenar JO Jr, Sullivan JL, Hammett EB, Zung WW. Analgesia and haloperidol: a hypothesis. J Clin Psychiatry 1979; 40: 323-6.
  57. Buttner M, Walder B, von Elm E, Tramer MR. Is low-dose haloperidol a useful antiemetic?: a meta-analysis of published and unpublished randomized trials. Anesthesiology 2004; 101: 1454-63. https://doi.org/10.1097/00000542-200412000-00028
  58. Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, Korjian S, Aouad MT. Haloperidol versus ondansetron for treatment of established nausea and vomiting following general anesthesia: a randomized clinical trial. Anesth Analg 2017; 124: 438-44. https://doi.org/10.1213/ANE.0000000000001723
  59. Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf 2010; 5: 257-62. https://doi.org/10.2174/157488610791698334
  60. Calver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings. Br J Clin Pharmacol 2014; 77: 880-6. https://doi.org/10.1111/bcp.12272
  61. Chou CC, Wu D. Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 2001; 24: 805-9.
  62. Siddique SM, Shariff N, Vesuwala N, Hafiz T. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med 2009; 150: 502-4. https://doi.org/10.7326/0003-4819-150-7-200904070-00016
  63. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 2009; 104 Suppl 2: S27-32. https://doi.org/10.1038/ajg.2009.49
  64. Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012; 21: 553-9. https://doi.org/10.1002/pds.3224
  65. Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83: 692-9. https://doi.org/10.1038/ki.2012.452
  66. Bibawy JN, Parikh V, Wahba J, Barsoum EA, Lafferty J, Kowalski M, et al. Pantoprazole (proton pump inhibitor) contributing to torsades de pointes storm. Circ Arrhythm Electrophysiol 2013; 6: e17-9. https://doi.org/10.1161/CIRCEP.112.000101
  67. Hasselgren B, Claar-Nilsson C, Hasselgren G, Niazi M, Svernhage E. Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin Drug Investig 2000; 20: 425-31. https://doi.org/10.2165/00044011-200020060-00005
  68. Asajima H, Saito N, Ohmura Y, Ohmura K. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide. Eur J Clin Pharmacol 2012; 68: 331-3. https://doi.org/10.1007/s00228-011-1119-z
  69. Tsubokura M, Miura Y, Itokawa T, Murata K, Takei N, Higaki T, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol 2011; 51: 1488-90. https://doi.org/10.1177/0091270010384483
  70. Liamis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med 2013; 126: 256-63. https://doi.org/10.1016/j.amjmed.2012.06.037
  71. Papademetriou V. Diuretics, hypokalemia, and cardiac arrhythmia: a 20-year controversy. J Clin Hypertens (Greenwich) 2006; 8: 86-92. https://doi.org/10.1111/j.1524-6175.2005.04722.x
  72. Singh BN, Hollenberg NK, Poole-Wilson PA, Robertson JI. Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death. J Hypertens 1992; 10: 301-16. https://doi.org/10.1097/00004872-199204000-00001
  73. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004; 27: 153-60. https://doi.org/10.1016/j.jemermed.2004.04.006
  74. Akita M, Kuwahara M, Tsubone H, Sugano S. ECG changes during furosemide-induced hypokalemia in the rat. J Electrocardiol 1998; 31: 45-9.

Cited by

  1. Opioid-induced constipation: a narrative review of therapeutic options in clinical management vol.32, pp.2, 2019, https://doi.org/10.3344/kjp.2019.32.2.69
  2. QT prolongation in HIV-positive patients: Review article vol.71, pp.6, 2018, https://doi.org/10.1016/j.ihj.2019.11.259